Selective Axillary Lymph Node Dissection Vs Complete Axillary Dissection: A Randomised Clinical Trial to Assess the Prevention of Lymphedema in Breast Cancer Treatment
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
To evaluate the efficacy, safety and cost reduction of SAD compared to standard ALND, we propose a prospective 2-arm randomised trial. The control arm consists of patients randomized to ALND, the study arm consists of patients randomized to SAD.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients diagnosed with operable breast cancer who are candidates for ALND, irrespective of the type of breast surgery performed or adjuvant treatments administered.
Patients who sign the informed consent form after explanation of trial aims by a senologist involved in the study.
Patients able to attend INT for regular follow-up as required by study protocol.
You may not be if
Massive axillary metastasis (N2 AJCC).
Previous surgery to controlateral axillary region.
Previous radiotherapy to ipsilateral or controlateral regional lymph nodes.
Non compliance with any inclusion criterion.
Clareo Health | Selective Axillary Lymph Node Dissection Vs Complete Axillary Dissection: A Randomised Clinical Trial to Assess the Prevention of Lymphedema in Breast Cancer Treatment
